Results 91 to 100 of about 492 (136)

Comparative Cardiotoxicity Profiles Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess

Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Comparative global pharmacovigilance evidence across anthracyclines, anti-HER2, and anti-VEGF therapies remains limited. Methods: A retrospective disproportionality study was conducted using Individual Case Safety
Esteban Zavaleta-Monestel, Sebastián Arguedas-Chacón, Jeaustin Mora-Jiménez, Jorge Arturo Villalobos-Madriz, Kevin Tencio-Morales, Brandon Enríquez-Gutiérrez   +5 more
openaire   +1 more source

Real-world safety signals of fezolinetant in women with menopausal vasomotor symptoms: a pharmacovigilance analysis of the WHO VigiAccess database

Objectives: To characterize the real-world safety profile of fezolinetant, a neurokinin-3 receptor antagonist approved for the treatment of menopausal vasomotor symptoms, using adverse event reports from the WHO ...
Xiaoling Gao, Lu Zhai, Shudan Deng, Lu Zhang, Bomeng Zhao, Huiyan Niu, Limantian Wang, Yan Li   +7 more
core   +1 more source

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy. This study assessed adverse drug reactions (ADRs) from both drugs, comparing their safety profiles to guide clinical use.MethodsA retrospective descriptive analysis was conducted on ADR reports ...
Yuanbin Huang, Meiqi Xu, Xinmiao Ma, Wei Wang, Chen Shen, Fei Liu, Zhiqi Chen, Jiawen Wang, Qian Guo, Xiancheng Li   +9 more
openaire   +3 more sources

Prevalencia de reacciones adversas a pirazinamida en afectados con tuberculosis en la zona 8 dentro del año 2019 [PDF]

, 2021
PdfLa tuberculosis representa una enfermedad infecciosa con un alto índice de mortalidad a nivel mundial, cuyo tratamiento emplea medicamentos de primera y segunda línea, dentro de los cuales se destaca la Isoniacida, Rifampicina, Etambutol, Kanamicina y
Morales González, Andrea Alexandra
core  

The real-world analysis of tinnitus-related adverse events across systemic medications: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

Background Tinnitus is a prevalent and often persistent symptom that imposes a substantial psychological and functional burden. Beyond disease-related mechanisms, accumulating real-world observations suggest that tinnitus may also ...
Zhuohao Li, Beiping Miao, Hongsong Dong, Guohui Nie, Yanping Yu   +4 more
core   +1 more source

Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study

African Health Sciences
Background: Multidrug-resistant tuberculosis (MDR-TB) is a prevalent health burden, both in South Africa and globally. The treatment of MDR-TB is both complex and difficult as multiple drugs have to be used concurrently in order to achieve good treatment outcomes for patients.
Singh, Lisa, Bangalee, Varsha, Ramasir, Serisha, John Mathibe, Lehlohonolo   +3 more
openaire   +4 more sources

Real-world study of adverse events associated with selumetinib based on the VigiAccess and FAERS databases

Abstract Background Selumetinib is the first drug approved for the treatment of neurofibromatosis type 1 (NF1). This study aims to evaluate the safety profile of selumetinib in real-world clinical settings. Methods Data on adverse events (AEs) associated with selumetinib was retrieved from the WHO-VigiAccess and FAERS databases ...
Feilong Tan, Wenjie Yin, Zhongjuan Wang, Lina You, Yanhua Li, Hongying Xia   +5 more
openaire   +1 more source

The safety profile of Vilazodone: a study on post-marketing surveillance. [PDF]

, 2020
Masters Degree. University of KwaZulu-Natal, Durban.Vilazodone was approved in 2011 as an antidepressant to treat major depressive disorder. Like other antidepressants, vilazodone has adverse effects associated with the use of the drug.
Kaja, Humraaz.
core  

Four table of measure of disproportionality.

BackgroundTranexamic acid (TXA) is an antifibrinolytic agent commonly used to mitigate blood loss across various medical indications. Despite its widespread use, comprehensive data on its safety profile remain limited.
Jing Feng (177843), Chiwei Guo (22569722), Shujuan Zhao (6317975)   +2 more
core   +1 more source

The READUS-PV checklist.

BackgroundTranexamic acid (TXA) is an antifibrinolytic agent commonly used to mitigate blood loss across various medical indications. Despite its widespread use, comprehensive data on its safety profile remain limited.
Jing Feng (177843), Chiwei Guo (22569722), Shujuan Zhao (6317975)   +2 more
core   +1 more source